Pharmacokinetic study of trans-resveratrol in adult pigs

Journal of Agricultural and Food Chemistry

Volumn 58, Issue 20, 2010, Pages 11165-11171

  Azorín Ortuno, María ^a   Yanez Gascon M J ^a   Pallarés, Francisco J ^b   Vallejo, Fernando ^a   Larrosa, Mar ^a   García Conesa, María Teresa ^a   Tomás Barberán, Francisco ^a   Espín, Juan Carlos ^a  

^a Research Group on Quality   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Bioavailability; Metabolism; Metabolites; Plasma; Polyphenol; Swine

Indexed keywords

AGLYCONES; BENEFICIAL EFFECTS; BIOAVAILABILITY; BODY WEIGHT; GLUCURONIDES; INFLUENCING FACTOR; LOW LEVEL; METABOLIC PROFILES; METHODOLOGICAL APPROACH; PHARMACOKINETIC STUDIES; PLASMA LEVELS; POLYPHENOLS; RESVERATROL; SWINE; TRANS-RESVERATROL;

ANIMALS; BIOCHEMISTRY; BIOMOLECULES; ISOMERS; METABOLITES; PHARMACOKINETICS; PHYSIOLOGY; PLASMAS;

METABOLISM;

ANIMALIA; SUIDAE;

RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; BLOOD; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SWINE; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; STILBENES; SWINE; TANDEM MASS SPECTROMETRY;

EID: 78049271002     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf102799m     Document Type: Article

References (45)

1. Baur, J. A.; Sinclair, D. A. Therapeutic potential or resveratrol: the in vivo evidence. Nat. Rev. 2006, 5, 493-506.
2. Espín, J. C.; García-Conesa, M. T.; Tomá s-Barberá n, F. A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68, 2986-3008.
3. Zamora-Ros, R.; Andres-Lacueva, C.; Lamuela-Raventó s, R. M.; Berenguer, T.; Jakszyn, P.; Martínez, C.; Sá nchez, M. J.; Navarro, C.; Chirlaque, M. D.; Tormo, M. J.; Quiró s, J. R.; Amiano, P.; Dorronsoro, M.; Larran" aga, N.; Barricarte, A.;Ardanaz, E.; Gonzá lez, C. A. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. Br. J. Nutr. 2008, 100, 188-196.
4. Kroon, P. A.; Iyer, A.; Chunduri, P.; Chan, V.; Brown, L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr. Med. Chem. 2010, 14, 2442-2455.
5. Andrés-Lacueva, C.; Urpí-Sardá , M.; Zamora-Ros, R.; Lamuela- Raventó s, R. M. Bioavailability and metabolism of resveratrol. In Plant Phenolics and Human Health: Biochemistry, Nutrition and Pharmacology; Fraga, C. G., Ed.; Wiley: Hoboken, NJ, 2009; pp 265- 299.
6. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
7. Gesher, A. J.; Steward, W. P. Relationship between mechanisms, bioavailability and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 953-957.
8. Sale, S.; Verschoyle, R. D.; Boocock, D.; Jones, D. J.; Wilsher, N.; Ruparelia, K. C.; Potter, G. A.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans-3,4,5,40-tetramethoxystilbene. Br. J. Cancer 2004, 90, 736-744.
9. Marier, J. F.; Vachon, P.; Gritsas, A.; Zhang, J.; Moreau, J. P.; Ducharme, M. P. Mtabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302, 369-373.
10. Goldberg, D. M.; Yan, J.; Soleas, G. J. Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36, 79-87.
11. Wenzel, E.; Somoza, V. Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
12. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7-16.
13. Guilloteau, P; Zabielski, R.; Hammon, H. M.; Metges, C. C. Nutritional programming of gastrointestinal tract development. Is the pig a good model for human? Nutr. Res. Rev. 2010, 23, 4-22.
14. Wu, X.; Pittman, H. E.; Prior, R. L. Fate of anthocynanins and antioxidant capacity in contents of the gastrointestinal tract of weanling pigs following black raspberry consumption. J. Agric. Food Chem. 2006, 54, 583-589.
15. Walton, M. C.; Lentle, R. G.; Reynolds, G. W.; Kruger, M. C.; McGhie, T. K. Anthocyanin absorption and antioxidant status in pigs. J. Agric. Food Chem. 2006, 54, 7940-7946.
16. Milbury, P. E.; Kalt, W. Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. J. Agric. Food Chem. 2010, 58, 3950-3956.
17. Ader, P.; Wessmann, A.; Wolffram, S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radical Biol. Med. 2000, 28, 1056-1067.
18. De Boer, V. C. J.; Dihal, A. A.; van der Woude, H.; Arts, I. C. W.; Wolffram, S.; Alink, G. M.; Rietjens, I. M. C. M.; Keijer, J.; Hollman, P. C. H. Tissue distribution of quercetin in rats and pigs. J. Nutr. 2005, 135, 1718-1725.
19. Bieger, J.; Cermak, R.; Blank, R.; de Boer, V. C. J.; Hollman, P. C. H.; Kamphues, J.; Wolffram, S. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J. Nutr. 2008, 138, 1417-1420.
20. Espín, J. C.; Gonzá lez-Barrio, B.; Cerdá , B.; Ló pez-Bote, C.; Rey, A. I.; Tomá s-Barberá n, F. A. The Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J. Agric. Food Chem. 2007, 55, 10476-10485.
21. Lucas, R.; Alcantara, D.; Morales, J. C. A concise synthesis of glucuronide metabolites of urolithin B, resveratrol and hydroxytyrosol. Carbohydr. Res. 2009, 344, 1340-1346.
22. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 2005, 49, 482-494.
23. Boocock, D.; Patel, K. R.; Faust, G. E. S.; Normolle, D. P.; Marczylo, T. H.; Crowell, J. A.; Brenner, D. E.; Booth, T. D.; Gescher, A.; Steward, W. P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007, 848, 182-187.
24. Juan, M. E.; Maijó , M.; Planas, J. M. Quantification of transresveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51, 391-398.
25. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22, 659-661.
26. Gu, L.; House, S. E.; Prior, R. L.; Fang, N.; Ronis, M. J.; Clarkson, T. B.; Wilson, M. E.; Badger, T. M. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J. Nutr. 2006, 136, 1215-1221.
27. Cerdá , B.; Espín, J. C.; Parra, S.; Martínez, P.; Tomá s-Barberá n, F. A. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur. J. Nutr. 2004, 43, 205-220.
28. Cerdá , B.; Tomá s-Barberá n, F. A.; Espín, J. C. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J. Agric. Food Chem. 2005, 53, 227-235.
29. Cerdá , B.; Soto, M. C.; Albaladejo, M. D.; Martínez, P.; Sá nchez- Gascó n, F.; Tomá s-Barberá n, F.; Espín, J. C. Pomegranate juice supplementation in COPD: a 5-week randomised, double blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2006, 60, 245-253.
30. Cerdá , B.; Llorach, R.; Ceró n, J. J.; Espín, J. C.; Tomá s-Barberá n, F. A. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur. J. Nutr. 2003, 42, 18-28.
31. Cerdá , B.; Ceró n, J. J.; Espín, J. C.; Tomá s-Barberá n, F. A. The repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J. Agric. Food Chem. 2003, 51, 3493-3501.
32. Meng, X.; Maliakal, P.; Lu, H.; Lee, M. J.; Yang, C. S. Urinary and plasma levels of resveratrol and quercetin in humans, mice and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem. 2004, 52, 935-942.
33. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P. P.; Fogliano, V.; Marchelli, R. Bioavailability of transresveratrol from red wine in humans. Mol. Nutr. Food Res. 2005, 49, 495-504.
34. Urpí-Sardà, M.; Já uregui, O.; Lamuela- Raventó s, R. M.; Jaeger, W.; Miksits, M.; Covas, M. I.; Andres-Lacueva, C. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 2005, 77, 3149-3155.
35. Burkon, A.; Somoza, V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol- C/O-conjugated diglucuronides. Two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 2008, 52, 549-557.
36. Boocock, D. J.; Faust, G. E.; Patel, K. R.; Schinas, A. M.; Brown, V. A.; Ducharme, M. P.; Booth, T. D.; Crowell, J. A.; Perloff, M.; Gescher, A. J.; Steward, W. P.; Brenner, D. E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
37. Patel, M.; Shah, T.; Amin, A. Therapeutic opportunities in colonspecific drug-delivery systems. Crit. Rev. Ther. Drug Carrier Sys. 2007, 24, 147-202.
38. Das, S.; Lin, H. S.; Ho, P. C.; Ng, K. Y. The impact of aqueous solubility and dose on the pharmacokinteci profiles of resveratrol. Pharm. Res. 2008, 25, 2593-2600.
39. Cassidy, A.; Brown, J. E.; Hawdon, A.; Faughnan, M. S.; King, L. J.; Millward, J.; Zimmer-Nechemias, L.; Wolfe, B.; Setchell, K. D. Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J. Nutr. 2006, 136, 45-51.
40. Alfaras, I.; Pé rez, M.; Juan,M. E.; Merino, G.; Prieto, J. G.; Planas, J. M.; Alvarez, A. I. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J. Agric. Food Chem. 2010, 58, 4523-4528.
41. Suzuki, T.; Zhao, Y. L.; Nadai, M.; Naruhashi, K.; Shimizu, A.; Takagi, K.; Hasegawa, T. Gender-related differences in expression and function of hepatic p-glycoprotein and multidrug resistanceassociated protein (Mrp2) in rats. Life Sci. 2006, 79, 455-461.
42. Miners, J. O.; McKinnon, R. A.; Mackenzie, P. I. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002, 181-182, 453-456.
43. Almeida, L.; Vaz-da-Silva, M.; Falc~ao, A.; Soares, E.; Costa, R.; Loureiro, A. I.; Fernandes-Lopes, C.; Rocha, J. F.; Nunes, T.; Wright, L.; Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53 (Suppl. 1), S7-S15.
44. Sweeney, B. P.; Bromilow, J. Liver enzyme induction and inhibition: implications for anaesthesia. Anaesthesia 2006, 61, 159-177.
45. Brett, G. M.; Hollands, W.; Needs, P. W.; Teucher, B.; Dainty, J. R.; Davis, B. D.; Brodbelt, J. S.; Kroon, P. A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br. J. Nutr. 2009, 101, 664-675.